Search

Elotuzumab

Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. … Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S.

Bardoxolone methyl

Vibriolysin

Vibriolysin is a proteolytic enzyme secreted by the marine microorganism Vibrio proteolyticus.

SR-123781A

It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

Dexloxiglumide

As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent. … Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.

MLN-977

It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.

RI 624

RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

Givinostat

In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.

AstraZeneca COVID-19 Vaccine

clots in association with thrombocytopenia - a causal link with the vaccine has not been proven, but is possible and requires further analysis. … Upon review, the European Medicines Agency (EMA) determined that the vaccine was not associated with a higher overall risk of blood clots, but that it may be associated with very rare instances of blood

Sitamaquine

Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential